What are the functions, efficacy and price of Lapatinib?

Lapatinib (Lapatinib), as a small molecule tyrosine kinase inhibitor, has been used in the global breast cancer targeted treatment system for many years. The main targets of this drug are HER2 and EGFR. By inhibiting the signaling pathway on the surface of tumor cells and reducing cell division activity, it exerts an inhibitory effect on breast cancer with overexpression of HER2. Its oral administration gives many late-stage patients more convenient treatment methods, and it has also become an integral part of the standard treatment plan in many countries. Although the domestic original drug has been withdrawn from the market, the therapeutic value of lapatinib is still recognized in international guidelines, especially for patients who still need to continue HER2 pathway inhibition after multiple lines of treatment. Lapatinib is still an important drug of choice.

In terms of action and efficacy, the most prominent feature of lapatinib is “dual target inhibition”, that is, it simultaneously blocks the downstream signals of ErbB2 and EGFR. Unlike some antibody drugs, it is a small molecule drug that can penetrate cell membranes, so it is more suitable for some patients who have a weak response to antibody-based targeted drugs. It is often used in combination with chemotherapy, combined with hormone therapy, or in combination with other HER2-targeted drugs to further enhance the tumor suppressive effect. Clinically, it is often used as a back-line option after previous treatment failure, but the order and priority of use may differ in different countries. Overseas guidelines emphasize that lapatinib still has certain value in combination with capecitabine, letrozole and other regimens, especially for patients who are more dependent on oral regimens, or for those who want to reduce the frequency of infusion therapy.

With the withdrawal of domestic original drugs from the market, the accessibility of lapatinib mainly relies on overseas channels. Price issues have become one of the most frequently asked questions by patients. At present, the international market is mainly divided into two categories: original drugs and generic drugs. In terms of original drugs, the Turkish version is currently one of the sources with lower prices and more stable supply. The regular specification is 0.25g*70 tablets. Its sales price under the local pharmaceutical system is relatively close to the people, which is about more than 2,000 yuan when converted into RMB. Since Türkiye implements a drug pricing restriction policy, the price of original drugs has not fluctuated significantly, making it the first choice for many patients looking for affordable solutions.

In addition to original drugs, generic drugs are also very common around the world, especially the versions in India and Bangladesh. The pharmaceutical systems of the two countries have accumulated many years of experience in generic targeted drugs, and the production standards, dosage specifications and active ingredients are basically consistent with the international original research versions. The price of the Indian version is about 600 yuan, and the price in Bangladesh is close to that in India. The main difference between the two is reflected in the brand and pharmaceutical factory management system. The consistency of the drug ingredients is higher, so it has become a more affordable alternative for many patients in long-term treatment. For patients who require long-term oral and continuous maintenance treatment, the economic advantages of the generic version are very obvious.

In the process of choosing lapatinib, the consistency of ingredients between different versions is a key concern for many patients. The active ingredient of lapatinib itself is a small molecule compound with a high degree of standardization, so it is not difficult to maintain consistency in generic versions in various countries. Generic drugs in India and Bangladesh are usually produced in strict accordance with the original dosage specifications, and corresponding quality supervision is implemented locally. Patients should try to avoid purchasing drugs through informal channels to avoid improper storage and transportation conditions that may affect drug stability and solubility.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html